Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 Exhibit 3.1
- 3.2 Exhibit 3.2
- 4.1 Exhibit 4.1
- 10.1 Exhibit 10.1
- 10.2 Exhibit 10.2
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.9 Exhibit 10.9
- 10.10 Exhibit 10.10
- 10.11 Exhibit 10.11
- 10.12 Exhibit 10.12
- 10.13 Exhibit 10.13
- 10.14 Exhibit 10.14
- 16.1 Exhibit 16.1
- 16.2 Exhibit 16.2
- 21.1 Exhibit 21.1
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
OSA similar filings
- 1 Mar 23 Departure of Directors or Certain Officers
- 1 Mar 23 ProSomnus® Appoints Brian Dow as Chief Financial Officer
- 1 Feb 23 ProSomnus® Provides Business Update and Preliminary 2022 Revenue Guidance
- 13 Dec 22 Entry into a Material Definitive Agreement
- 8 Dec 22 Study Published in Military Medicine Reports 88% Success Treating Obstructive Sleep Apnea Patients with Precision Oral Appliance Therapy
- 6 Dec 22 Regulation FD Disclosure
Filing view
External links
Exhibit 16.1
December 12, 2022
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K filed with the U.S. Securities and Exchange Commission on December 12, 2022 of ProSomnus, Inc. (the “Company”) and agree with the statements relating only to UHY LLP contained therein. We have no basis to agree or disagree with other statements of the Company contained therein.
We hereby consent to the filing of this letter as an exhibit to the foregoing report on Form 8-K.
/s/ UHY LLP